Picture/Labiotech

Pre Diagnostics AS is a brand new Norwegian firm creating and commercializing an progressive and efficient diagnostic take a look at for Alzheimer’s illness (AD). 

Based by an skilled biotech workforce, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic take a look at from the Norwegian college hospital AHUS.

The corporate stated it would pursue cost-efficient product growth with exterior companions, enabling public funding alternatives; collaborate with AHUS researchers on medical growth trials; and pursue gross sales to main pharma firms along with famend diagnostic firms.

Pre Diagnostics stated it seeks to create worth for sufferers, companions and traders by creating pioneering and patient-friendly in-vitro diagnostic (IVD) merchandise for early detection of illnesses.

The corporate’s proprietary idea exhibits {that a} illness evokes systemic responses in macrophages within the blood distinctive to a particular illness that may be precisely measured by means of blood samples.

Pre Diagnostics goals to be a pacesetter in diagnosing early Alzheimer’s illness and is concentrated on the event of IVD biomarker merchandise that use established and efficient applied sciences and procedures.

We spoke with the corporate’s co-founder and CEO, Håkon Sæterøy, at NLS Days in Malmö.

Source link